Rhythm Pharmaceuticals/$RYTM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Ticker
$RYTM
Sector
Primary listing
Employees
414
Headquarters
Website
RYTM Metrics
BasicAdvanced
$6B
-
-$3.11
2.15
-
Price and volume
Market cap
$6B
Beta
2.15
52-week high
$122.20
52-week low
$45.91
Average daily volume
912K
Financial strength
Current ratio
4.407
Quick ratio
3.918
Long term debt to equity
38.599
Total debt to equity
41.542
Interest coverage (TTM)
-9.33%
Profitability
EBITDA (TTM)
-190.678
Gross margin (TTM)
89.73%
Net profit margin (TTM)
-103.57%
Operating margin (TTM)
-101.19%
Effective tax rate (TTM)
-0.25%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
-27.51%
Return on equity (TTM)
-90.45%
Valuation
Price to revenue (TTM)
29.948
Price to book
42.26
Price to tangible book (TTM)
43.94
Price to free cash flow (TTM)
-36.283
Free cash flow yield (TTM)
-2.76%
Free cash flow per share (TTM)
-2.41
Growth
Revenue change (TTM)
45.83%
Earnings per share change (TTM)
-28.37%
3-year revenue growth (CAGR)
100.23%
3-year earnings per share growth (CAGR)
-3.66%
10-year earnings per share growth (CAGR)
10.20%
What the Analysts think about RYTM
Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.
RYTM Financial Performance
Revenues and expenses
RYTM Earnings Performance
Company profitability
RYTM News
AllArticlesVideos
Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
Investors Business Daily·1 day ago
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial
Reuters·5 days ago
Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market
Benzinga·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rhythm Pharmaceuticals stock?
Rhythm Pharmaceuticals (RYTM) has a market cap of $6B as of March 21, 2026.
What is the P/E ratio for Rhythm Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of March 21, 2026.
Does Rhythm Pharmaceuticals stock pay dividends?
No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of March 21, 2026.
When is the next Rhythm Pharmaceuticals dividend payment date?
Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) has a beta rating of 2.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.